Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2018 · 10-Q
Revenue$3.17M$3.17M+8.8% vs Q2 2017 Net Income-$1.01M-$1.01MN/M vs Q2 2017 EPS Diluted-$0.02-$0.02N/M vs Q2 2017 Gross Profit$579,481−10.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$399,340N/M Free Cash Flowderived-$425,695N/M Margins · derivedGross margin18.3%−4.0 pt vs Q2 2017
Operating margin-27.2%+45.8 pt vs Q2 2017
Net margin-31.8%+46.7 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end